Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hamlet BioPharma AB publFRA:7ZT 31 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates FRA:7ZT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 845 Biotechnology companies, Hamlet BioPharma AB publ ranks worse than 118343.08% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Hamlet BioPharma AB publ's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Hamlet BioPharma AB publ's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.00 Mil.
Hamlet BioPharma AB publ (FRA:7ZT) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Hamlet BioPharma AB publ Receivables Turnover Related Terms
Hamlet BioPharma AB publ Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Hamlet BioPharma AB publ's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamlet BioPharma AB publ Receivables Turnover Chart
FRA:7ZT vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Hamlet BioPharma AB publ's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hamlet BioPharma AB publ Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hamlet BioPharma AB publ's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Hamlet BioPharma AB publ's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hamlet BioPharma AB publ (FRA:7ZT) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hamlet BioPharma AB publ and its competitors. According to the industry distribution chart, Hamlet BioPharma AB publ ranks #999999 out of 845 companies in the Biotechnology industry.
Is Hamlet BioPharma AB publ's Receivables Turnover too high?
Hamlet BioPharma AB publ's current Receivables Turnover is 0.00. Based on the distribution chart, Hamlet BioPharma AB publ ranks #999999 out of 845 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hamlet BioPharma AB publ ranks #999999 out of 845 companies for Receivables Turnover. This places Hamlet BioPharma AB publ in the lower half of its industry. The industry median Receivables Turnover is 5.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.22, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hamlet BioPharma AB publ and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamlet BioPharma AB publ's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (FRA:7ZT) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Hamlet BioPharma AB publ (FRA:7ZT), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7ZT has been successfully added to your 
